Literature DB >> 10348061

The threat of vancomycin resistance.

T M Perl1.   

Abstract

Vancomycin, produced in 1958, an essential antibiotic in the modern age, often is reserved for use in patients who are gravely ill or for infections caused by organisms resistant to penicillin, cephalosporin, or other antibiotics. Bacterial resistance to vancomycin has caused great concern among many healthcare professionals. First reported in 1986 in Europe and in 1988 in the United States, vancomycin-resistant enterococci (VRE) have become a major cause of nosocomial infections. During this time, scattered reports of clinical infections caused by vancomycin-resistant coagulase-negative staphylococci also were reported. Recently, enterococci that require vancomycin in media for growth, vancomycin-dependent enterococci (VDE), have been reported to cause clinically significant infections. Vancomycin or other glycopeptide intermediately resistant Staphylococcus aureus (VISA/GISA) also has emerged. The mechanisms of resistance to vancomycin for VRE, and probably for VISA/GISA, relate to the acquired ability of these organisms to circumvent the vancomycin-mediated disruption of bacterial cell wall synthesis. Risk factors that lead to VRE colonization or infection include prior antibiotic therapy, prolonged hospitalization, hospitalization in an intensive care unit, concomitant serious medical and surgical illnesses, exposure to equipment contaminated with VRE, and exposure to patients with VRE. Patients colonized or infected with VRE, healthcare workers with contaminated hands, and environmental surfaces in healthcare facilities are major reservoirs of VRE. Risk factors for VDE and VISA/GISA are less well understood, although both organisms emerge in patients receiving vancomycin or other glycopeptide antibiotics. Infection and antibiotic control procedures for both organisms, including restriction of vancomycin use, optimization of the antibiotic formulary, education of hospital personnel, early detection and reporting of vancomycin resistance, isolation of colonized patients, and appropriate cleansing of the environment are used to prevent the spread of these organisms in healthcare settings.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348061     DOI: 10.1016/s0002-9343(98)00354-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  22 in total

1.  Synthetic peptide immunogens elicit polyclonal and monoclonal antibodies specific for linear epitopes in the D motifs of Staphylococcus aureus fibronectin-binding protein, which are composed of amino acids that are essential for fibronectin binding.

Authors:  M Huesca; Q Sun; R Peralta; G M Shivji; D N Sauder; M J McGavin
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

2.  Vancomycin-resistant enterococci in Canada revisited.

Authors:  B L Johnston; J M Conly
Journal:  Can J Infect Dis       Date:  2000-05

Review 3.  Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update.

Authors:  Bradley A Warady; Sevcan Bakkaloglu; Jason Newland; Michelle Cantwell; Enrico Verrina; Alicia Neu; Vimal Chadha; Hui-Kim Yap; Franz Schaefer
Journal:  Perit Dial Int       Date:  2012-06       Impact factor: 1.756

4.  In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.

Authors:  S Chamberland; J Blais; M Hoang; C Dinh; D Cotter; E Bond; C Gannon; C Park; F Malouin; M N Dudley
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

5.  7-O-malonyl macrolactin A, a new macrolactin antibiotic from Bacillus subtilis active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and a small-colony variant of Burkholderia cepacia.

Authors:  Magally Romero-Tabarez; Rolf Jansen; Marita Sylla; Heinrich Lünsdorf; Susanne Häussler; Dwi A Santosa; Kenneth N Timmis; Gabriella Molinari
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

6.  The Galactose-Binding Lectin Isolated from Vatairea macrocarpa Seeds Enhances the Effect of Antibiotics Against Staphylococcus aureus-Resistant Strain.

Authors:  Valdenice F Santos; Maria S Costa; Fábia F Campina; Renato R Rodrigues; Ana L E Santos; Felipe M Pereira; Karla L R Batista; Rafael C Silva; Raquel O Pereira; Bruno A M Rocha; Henrique D M Coutinho; Claudener S Teixeira
Journal:  Probiotics Antimicrob Proteins       Date:  2020-03       Impact factor: 4.609

7.  Reassessing the role of Staphylococcus aureus clumping factor and fibronectin-binding protein by expression in Lactococcus lactis.

Authors:  Y A Que; P François; J A Haefliger; J M Entenza; P Vaudaux; P Moreillon
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

8.  Effects of SCH27899 (Ziracin), an oligosaccharide everninomicin antibiotic, on urate kinetics in humans.

Authors:  Satoru Nagashima; Masayuki Niwa; Katsuyuki Nishiki; Tatsuo Hosoya; Akira Hishida; Toshihiko Uematsu
Journal:  Eur J Clin Pharmacol       Date:  2004-04-16       Impact factor: 2.953

Review 9.  Vancomycin resistance in staphylococci.

Authors:  Arjun Srinivasan; James D Dick; Trish M Perl
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

10.  Mannopeptimycins, new cyclic glycopeptide antibiotics produced by Streptomyces hygroscopicus LL-AC98: antibacterial and mechanistic activities.

Authors:  M P Singh; P J Petersen; W J Weiss; J E Janso; S W Luckman; E B Lenoy; P A Bradford; R T Testa; M Greenstein
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.